EXAS SEC-arkiveringar - Exact Sciences Corporation- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

LEI	549300VM3X1FYD4N9Z14
CIK	1124140

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Exact Sciences Corporation

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

April 2, 2026	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 Exact Sciences Corporation (Exact name of registrant as spe
March 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 EXACT SCIENCES CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
March 23, 2026	EX-3.1	SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION EXACT SCIENCES CORPORATION ARTICLE I EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EXACT SCIENCES CORPORATION * * * ARTICLE I The name of the corporation (hereinafter called the “Corporation”) is Exact Sciences Corporation. ARTICLE II The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of N
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	EX-4.1	SIXTH SUPPLEMENTAL INDENTURE EX-4.1 Exhibit 4.1 SIXTH SUPPLEMENTAL INDENTURE THIS SIXTH SUPPLEMENTAL INDENTURE (this “Sixth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Comp
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	EX-3.2	EIGHTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION ARTICLE I EX-3.2 Exhibit 3.2 EIGHTH AMENDED AND RESTATED BYLAWS OF EXACT SCIENCES CORPORATION (Delaware) * * * ARTICLE I Offices Section 1.1 Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action of the board of directors. Section 1.2 Other
March 23, 2026	EX-4.4	NINTH SUPPLEMENTAL INDENTURE EX-4.4 Exhibit 4.4 NINTH SUPPLEMENTAL INDENTURE THIS NINTH SUPPLEMENTAL INDENTURE (this “Ninth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture,
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	POSASR	As filed with the Securities and Exchange Commission on March 23, 2026 POSASR As filed with the Securities and Exchange Commission on March 23, 2026 Registration No.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	EX-4.3	EIGHTH SUPPLEMENTAL INDENTURE EX-4.3 Exhibit 4.3 EIGHTH SUPPLEMENTAL INDENTURE THIS EIGHTH SUPPLEMENTAL INDENTURE (this “Eighth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indentur
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	EX-4.2	SEVENTH SUPPLEMENTAL INDENTURE EX-4.2 Exhibit 4.2 SEVENTH SUPPLEMENTAL INDENTURE THIS SEVENTH SUPPLEMENTAL INDENTURE (this “Seventh Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, th
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 23, 2026	S-8 POS	As filed with the Securities and Exchange Commission on March 23, 2026 S-8 POS As filed with the Securities and Exchange Commission on March 23, 2026 Registration Nos.
March 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 EXACT SCIENCES CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
February 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 EXACT SCIENCES CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2026 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
February 17, 2026	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
February 13, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re
February 13, 2026	EX-21	SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
February 13, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2026 EXACT SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2026 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
February 13, 2026	EX-99.1	Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results Fourth quarter and 2025 highlights •Total fourth quarter revenue of $878 million, an increase of 23% o
February 10, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 EXACT SCIENCES CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2026 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
February 10, 2026	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 30, 2026	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 23, 2026	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
January 9, 2026	DEFM14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFM14A Table of Contents Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
December 29, 2025	EX-10.1	Form of Acceleration and Clawback Agreement EX-10.1 Exhibit 10.1 Form of Acceleration and Clawback Agreement As you are aware, on November 19, 2025, Exact Sciences Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (as it may be amended, the “Merger Agreement”), with Abbott Laboratories, an Illinois corporation (“Parent”), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, whol
December 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 EXACT SCIENCES CO DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
December 29, 2025	PREM14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PREM14A Table of Contents Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
December 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 EXACT SCIENCES CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2025 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
December 29, 2025	EX-FILING FEES	Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 21,009,159,147.
November 26, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 24, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 EXACT SCIENCES CO DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
November 20, 2025	EX-99.1	1 EX-99.1 Exhibit 99.1 Press Release Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments • Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments • Acquisition will uniq
November 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 EXACT SCIENCES CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
November 20, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	DEFA14A	Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
November 20, 2025	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG ABBOTT LABORATORIES, BADGER MERGER SUB I, INC. EXACT SCIENCES CORPORATION DATED AS OF NOVEMBER 19, 2025 EX-2.1 Exhibit 2.1* AGREEMENT AND PLAN OF MERGER BY AND AMONG ABBOTT LABORATORIES, BADGER MERGER SUB I, INC. AND EXACT SCIENCES CORPORATION DATED AS OF NOVEMBER 19, 2025 * The copy of the Agreement and Plan of Merger in this Exhibit 2.1 (the “Merger Agreement”) has been included to provide investors with information regarding the terms of the Merger Agreement. It is not intended to provide any oth
November 3, 2025	EX-99.1	Exact Sciences Announces Third Quarter 2025 Results Reports record revenue, raises full-year guidance, generates record cash from operations EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Third Quarter 2025 Results Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights
November 3, 2025	EX-3.4	EIGHTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION (As of October 29, 2025) TABLE OF CONTENTS EXHIBIT 3.4 EIGHTH AMENDED AND RESTATED BYLAWS OF EXACT SCIENCES CORPORATION (As of October 29, 2025) BYLAWS TABLE OF CONTENTS Page Article 1 STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETING 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 1 1.6 QUORUM 2 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 2 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3 1.
November 3, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac
November 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 EXACT SCIENCES C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
October 9, 2025	144	144 144 0001614265 XXXXXXXX LIVE 0001124140 EXACT SCIENCES CORP 001-35092 5505 ENDEAVOR LANE MADISON WI 53719 608-284-5700 Doyle James Edward Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2000 120000.
October 9, 2025	144	144 144 0001957680 XXXXXXXX LIVE 0001124140 EXACT SCIENCES CORP 001-35092 5505 ENDEAVOR LANE MADISON WI 53719 608-284-5700 Herriott James Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 1500 90000.
August 6, 2025	EX-10.5	SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.5 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Aaron Bloomer (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined b
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 EXACT SCIENCES COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
August 6, 2025	EX-10.6	THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.6 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Sarah Condella (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined be
August 6, 2025	EX-10.3	EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Deferred Stock Unit Award Agreement EXHIBIT 10.3 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Deferred Stock Unit Award Agreement Granted To: #ParticipantName# Grant Date: #GrantDate# Number of Deferred Stock Units: #QuantityGranted# This Deferred Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Co
August 6, 2025	EX-10.4	SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Brian Baranick (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined
August 6, 2025	EX-99.2	Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome su EXHIBIT 99.2 Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests Exact Sciences acquires exclusive rights to current and future versions of Freenome’s blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences’ leadersh
August 6, 2025	EX-99.1	Exact Sciences Announces Second Quarter 2025 Results Reports record revenue, improves adjusted EBITDA, raises full-year guidance EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Second Quarter 2025 Results Reports record revenue, improves adjusted EBITDA, raises full-year guidance Second quarter and recent highlights •Delivered
August 6, 2025	EX-10.7	SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of August 5, 2025, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Jacob Orville (“Employee”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined b
July 11, 2025	EX-4.8	EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Award Agreement EXHIBIT 4.8 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Award Agreement Granted To: Grant Date: Number of Restricted Stock Units: This Global Restricted Stock Unit Award Agreement, including any country-specific terms and conditions set forth in Exhibit B hereto (the “Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (th
July 11, 2025	EX-4.10	EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Award Agreement EXHIBIT 4.10 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Award Agreement Granted To: Grant Date: Number of Restricted Stock Award: Fair Market Value Per Share: This Restricted Stock Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”) and you (“Grantee”). The Company sponsors the 2025 Omnibus Lo
July 11, 2025	S-8	As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No.
July 11, 2025	S-8 POS	As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No.
July 11, 2025	EX-4.9	EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Performance Share Unit (PSU) Award Agreement EXHIBIT 4.9 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Performance Share Unit (PSU) Award Agreement Grantee: Grant Date: Maximum Number of Performance Share Units (PSUs): Target Number of Performance Share Units (PSUs): This Global Performance Share Unit Award Agreement, including any country-specific terms and conditions set forth in Exhibit B hereto (the “Award Agreement”)
July 11, 2025	EX-FILING FEES	Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri
June 24, 2025	11-K	United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PUR
June 16, 2025	EX-10.2	AMENDMENT EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) EXHIBIT 10.2 AMENDMENT TO EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) AMENDMENT (the "Amendment"), dated April 15, 2025, to the 2010 Employee Stock Purchase Plan (As amended and restated on July 31, 2024) (the "Existing Plan"; as amended hereby, the "Plan"), of EXACT SCIENCES CORPORATION, a Delaware corporation (the "Company"). Statement
June 16, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 16, 2025	EX-10.1	EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 EXACT SCIENCES CORPORATION 2025 OMNIBUS LONG-TERM INCENTIVE PLAN Exact Sciences Corporation, a Delaware corporation (the “Company”), sets forth herein the terms of its 2025 Omnibus Long-Term Incentive Plan (as may be amended from time to time, the “Plan”), as follows: 1. PURPOSE The Plan is intended to enhance the Company’s and its Affiliates’ (as defined herein) ability to attract an
May 1, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na
May 1, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File
May 1, 2025	EX-99.1	Exact Sciences Announces First-Quarter 2025 Results EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces First-Quarter 2025 Results First quarter highlights •Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core r
April 29, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of registrant as specif
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐
April 29, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
February 19, 2025	EX-19	EXACT SCIENCES CORPORATION INSIDER TRADING POLICY EXHIBIT 19 EXACT SCIENCES CORPORATION INSIDER TRADING POLICY Exact Sciences Corporation (“Exact”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal securities laws by members of Exact’s Board of Directors, officers, employees, contractors and consultants of Exact and its affiliates, as well as any immediate family members sharing the household of any of the foregoing, and any entities controlled by any of the foregoing persons, including corporations, partnerships or trusts (collectively, “Exact Personnel”).
February 19, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
February 19, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re
February 19, 2025	EX-21	SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
February 19, 2025	EX-10.35	Exact Sciences Corporation Executive Officer Perquisite Policy Exact Sciences Corporation Executive Officer Perquisite Policy This Exact Sciences Corporation (the “Company”) Perquisite Policy (the “Policy”), effective December 13, 2024, sets forth the Company’s perquisite policy for Executive Officers.
February 19, 2025	EX-99.1	Exact Sciences Announces Fourth Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. [email protected] 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Fourth Quarter 2024 Results Fourth quarter and 2024 highlights •Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core reve
February 19, 2025	EX-10.30	Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.30 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Exact Sciences Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
January 13, 2025	EX-99.1	Exact Sciences Announces Preliminary Fourth Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2024 Results Highlighted announcements: •Expects total fourth quarter revenue of $713 million, an increase of 10% compared
January 13, 2025	EX-10.1	CREDIT AGREEMENT dated as of January 13, 2025 EXACT SCIENCES CORPORATION, as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO JPMORGAN CHASE BANK, N.A., as Administrative Agent, JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC. and PNC BANK, N EXHIBIT 10.1 CREDIT AGREEMENT dated as of January 13, 2025 among EXACT SCIENCES CORPORATION, as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO JPMORGAN CHASE BANK, N.A., as Administrative Agent, and JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC. and PNC BANK, NATIONAL ASSOCIATION, As Joint Lead Arrangers and Joint Bookrunners and CIBC BANK USA, CITIBANK, N.A., CRÉDIT AGRICOLE CORPORATE
January 13, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 6, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
November 13, 2024	SC 13G	EXAS / Exact Sciences Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Exact Sciences Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
November 8, 2024	EX-99	JOINT FILING AGREEMENT EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Exact Sciences Corporation is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-
November 8, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Exact Sciences Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat
November 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac
November 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
November 5, 2024	EX-10.3	FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.3 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Brian Baranick. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS
November 5, 2024	EX-10.2	FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Jacob Orville. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS
November 5, 2024	EX-99.1	Exact Sciences Announces Third-Quarter 2024 Results Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Steph Spanos Exact Sciences Corp. [email protected] 608-556-4380 For Immediate Release Exact Sciences Announces Third-Quarter 2024 Results Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights •Total third
November 5, 2024	EX-10.5	EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) EXHIBIT 10.5 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on July 31, 2024) Article 1—Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined i
November 5, 2024	EX-10.1	FIRST AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Aaron Bloomer. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITALS
November 5, 2024	EX-10.4	SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”) is entered into as of July 31, 2024, by and between Exact Sciences Corporation, a Delaware corporation (the “Company”), and Sarah Condella. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Employment Agreement (as defined below). RECITA
October 7, 2024	SC 13G	EXAS / Exact Sciences Corporation / FMR LLC Passive Investment SCHEDULE 13G Amendment No.0 EXACT SCIENCES CORP COMMON STOCK Cusip #30063P105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #30063P105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 21,499,163 Item 6: 0 Item 7: 22,042,464 Item 8: 0 Item 9: 22,042,464 Item 11:
October 4, 2024	EX-99.1	JOINT FILING AGREEMENT MDxHealth SA EX-99.1 2 exas-20241004xex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT MDxHealth SA In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby confirm the agreement by and among them to the joint filing on behalf of them of the Statement on Schedule 13G and any and all further amendments thereto, with respect to the se
October 4, 2024	SC 13G	MDXH / MDxHealth SA / Exact Sciences Corp - SC 13G Passive Investment SC 13G 1 exas-20241004xsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * MDXHEALTH SA (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) B5950S113 (CUSIP Number) September 27, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo
July 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam
July 31, 2024	EX-99.1	Exact Sciences Announces Second-Quarter 2024 Results Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance EXHIBIT 99.1 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second-Quarter 2024 Results Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second
July 31, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 25, 2024	11-K	United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PUR
June 17, 2024	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 7, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / JPMORGAN CHASE & CO - FILING EXACT SCIENCES CORPORATION Passive Investment SC 13G/A 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) May 31, 2024 (Date of Event Which Requi
June 3, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 8, 2024	424B7	EXACT SCIENCES CORPORATION 5,570,132 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated May 25, 2023) EXACT SCIENCES CORPORATION 5,570,132 Shares of Common Stock This prospectus supplement relates to the resale of up to 5,570,132 shares of our common stock, par value $0.
May 8, 2024	EX-99.1	Exact Sciences Announces First-Quarter 2024 Results EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces First-Quarter 2024 Results First quarter highlights •Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File
May 8, 2024	EX-10.1	EMPLOYMENT AGREEMENT EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into effective as of April 15, 2024 (the “Effective Date”), by and between Aaron Bloomer (“Employee”) and Exact Sciences Corporation, a Delaware corporation (the “Company,” and together with Employee, the “Parties”). WHEREAS, the Company desires to employ Employee as its Chief Financial Officer, and Employee desir
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na
May 8, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File
May 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables ……424(b)(7)…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒
April 25, 2024	ARS	ARS ,% +++ ,) + %/%&$$ ** &% .3E:;@9FA@ 222222222222222222222222222222222222222222222222222222222222222 22222222222222 &)$ " %%,#)'&)+',),%++&+ &% &) 6&+,) + /%+ & ADF:78;E53>K73D7@676757?47D +)%* + &%)'&)+',),%++&+ &% &) 6&+,) + /% +& A??;EE;A@8;>7@
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐
April 25, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
April 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 EXACT SCIENCES COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
April 17, 2024	EX-4.2	EXACT SCIENCES CORPORATION 1.75% Convertible Senior Notes due 2031 FIFTH SUPPLEMENTAL INDENTURE Dated as of April 17, 2024 Dated as of January 17, 2018 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS EXHIBIT 4.2 EXACT SCIENCES CORPORATION 1.75% Convertible Senior Notes due 2031 FIFTH SUPPLEMENTAL INDENTURE Dated as of April 17, 2024 to INDENTURE Dated as of January 17, 2018 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE 1 Scope of Fifth Supplemental Indenture; Definitions 1 SECTION 1.01. Scope of Fifth Supplemental Indenture 1 SECTION 1.02. Definitions
April 17, 2024	EX-99.1	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024 — Exact Sciences Corp. (Nasdaq: EXAS) (the “Co
April 15, 2024	EX-99.1	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wisc., April 15, 2024 – Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previ
April 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 EXACT SCIENCES COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
February 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
February 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re
February 21, 2024	EX-10.33	EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY EXHIBIT 10.33 EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY 1.Introduction. This Equity Award Death, Disability and Retirement Policy, as amended (the “Policy”), specifies the treatment of each outstanding equity award (an “Equity Award”) granted by Exact Sciences Corporation, a Delaware corporation (including any successor thereto, the “Company”), in the event of
February 21, 2024	EX-21	SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
February 21, 2024	EX-99.1	Exact Sciences Announces Fourth Quarter 2023 Results Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Fourth Quarter 2023 Results Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quar
February 21, 2024	EX-97	EXACT SCIENCES CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY EXHIBIT 97 EXACT SCIENCES CORPORATION INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1.
February 13, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0891-exactsciencescorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Exact Sciences Corp Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to design
February 9, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate
January 29, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / BlackRock Inc. Passive Investment SC 13G/A 1 us30063p1057012924.txt us30063p1057012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) EXACT SCIENCES CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 30063P105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo
January 23, 2024	SC 13G/A	EXAS / Exact Sciences Corporation / JPMORGAN CHASE & CO - FILING EXACT SCIENCES CORPORATION Passive Investment SC 13G/A 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) December 29, 2023 (Date of Event Which
January 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 8, 2024	EX-99.1	Exact Sciences Announces Preliminary Fourth Quarter 2023 Results Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan EXHIBIT 99.1 Investor Contact: Nathan Harrill Exact Sciences Corp. [email protected] 608-535-8659 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2023 Results Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits nex
November 1, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
November 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac
November 1, 2023	EX-99	Exact Sciences Announces Third-Quarter 2023 Results Reports record revenue, delivers more than a million test results, raises full-year guidance EXHIBIT 99 Investor Contact: Erik Holznecht Exact Sciences Corp. [email protected] 608-800-6605 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Third-Quarter 2023 Results Reports record revenue, delivers more than a million test results, raises full-year guidance Third-quarter 2023 highli
October 10, 2023	SC 13G	EXAS / Exact Sciences Corp. / JPMORGAN CHASE & CO - FILING EXACT SCIENCES CORPORATION Passive Investment SC 13G 1 EXACTSCIENCESCORPORATION.htm FILING EXACT SCIENCES CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 30063P105 (CUSIP Number) September 29, 2023 (Date of Event Which Req
August 1, 2023	EX-10.5	EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Deferred Stock Unit Award Agreement GRANTED TO GRANT DATE NUMBER OF DEFERRED STOCK UNITS EXHIBIT 10.5 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Deferred Stock Unit Award Agreement GRANTED TO GRANT DATE NUMBER OF DEFERRED STOCK UNITS This Deferred Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Company. The Company maintains the Exact
August 1, 2023	EX-FILING FEES	Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri
August 1, 2023	EX-10.2	Exact Sciences Corporation Incentive Stock Option Award Agreement Cover Sheet EXHIBIT 10.2 Exact Sciences Corporation Incentive Stock Option Award Agreement Cover Sheet Exact Sciences Corporation, a Delaware corporation, hereby grants to you (the Grantee named below), and you hereby accept, an Option on the following terms and subject to the terms and conditions specified in the attached Terms and Conditions Controlling Plan: Exact Sciences Corporation 2019 Omnibus Long-Ter
August 1, 2023	EX-99	Exact Sciences Announces Second-Quarter 2023 Results Reports record results, generates positive free cash flow, raises full-year guidance Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second-Quarter 2023 Results Reports record results, generates positive free cash flow, raises full-year guidance Second-quarter 2023 highlights •Total seco
August 1, 2023	EX-10.3	EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Unit Award Agreement Exhibit 10.3 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Unit Award Agreement Granted To: Grant Date: Number of Restricted Stock Units: This Restricted Stock Unit Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation (the “Company”), and you, a Service Provider to the Company (“Grantee”). The Company
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
August 1, 2023	EX-10.4	EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Award Agreement GRANTED TO GRANT DATE NUMBER OF SHARES EXHIBIT 10.4 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN, AS AMENDED Restricted Stock Award Agreement GRANTED TO GRANT DATE NUMBER OF SHARES This Restricted Stock Award Agreement (“Award Agreement”) is made between Exact Sciences Corporation, a Delaware corporation, (the “Company”) and you (“Grantee”). The Company sponsors the 2019 Omnibus Long-Term Incentive Plan, as amended
August 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam
August 1, 2023	S-8	As filed with the Securities and Exchange Commission on August 1, 2023 As filed with the Securities and Exchange Commission on August 1, 2023 Registration No.
June 27, 2023	11-K	United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PUR
June 21, 2023	EX-99.1	June 21, 2023 We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or exas-20230621ex991 June 21, 2023 We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment.
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 EXACT SCIENCES CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 EXACT SCIENCES CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 12, 2023	EX-10.1	AMENDMENT NO. 2 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 AMENDMENT NO. 2 TO EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN This AMENDMENT NO. 2 (the “Amendment”) amends the 2019 Omnibus Long-Term Incentive Plan (as previously amended, the “Existing Plan”; as amended hereby, the “Plan”) of EXACT SCIENCES CORPORATION, a Delaware corporation (the “Company”). Statement of Purpose The Existing Plan was originally approved by th
June 12, 2023	EX-3.1	CERTIFICATE OF AMENDMENT TO SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION EXACT SCIENCES CORPORATION EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EXACT SCIENCES CORPORATION EXACT SCIENCES CORPORATION, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies that: FIRST: This Certificate of Amendment amends the provisions of the Corporation’s Sixth Amended and Restated Certificate of Inc
June 12, 2023	EX-3.2	SEVENTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION (As of June 9, 2023) TABLE OF CONTENTS Page Article 1 STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETINGS 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 2 1.6 QUORUM 2 Exhibit 3.2 SEVENTH AMENDED AND RESTATED BY-LAWS OF EXACT SCIENCES CORPORATION (As of June 9, 2023) BY-LAWS TABLE OF CONTENTS Page Article 1 STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETINGS 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 2 1.6 QUORUM 2 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 3 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3 1.
May 25, 2023	S-3ASR	As Filed With the Securities and Exchange Commission on May 25, 2023 Table of Contents As Filed With the Securities and Exchange Commission on May 25, 2023 Registration No.
May 25, 2023	EX-FILING FEES	Calculation of Filing Fee Tables ……Form S-3ASR…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables ……Form S-3ASR…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate A
May 25, 2023	EX-25	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Exhibit 25 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) ☐ U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. Emp
May 9, 2023	EX-99	Exact Sciences Announces First Quarter 2023 Results Reports record results, raises full-year guidance, accelerates path to positive free cash flow Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces First Quarter 2023 Results Reports record results, raises full-year guidance, accelerates path to positive free cash flow First quarter highlights •Total f
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 EXACT SCIENCES CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File
May 9, 2023	EX-10.2	EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 22, 2023) EXHIBIT 10.2 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 22, 2023) Article 1-Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined
May 9, 2023	EX-10.3	Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.3 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company
April 26, 2023	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of registrant as specif
April 26, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
April 26, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 14, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 EXACT SCIENCES COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
March 17, 2023	424B7	EXACT SCIENCES CORPORATION 5,171,577 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated June 1, 2020) EXACT SCIENCES CORPORATION 5,171,577 Shares of Common Stock This prospectus supplement relates to the resale of up to 5,171,577 shares of our common stock, par value $0.
March 17, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables ……424(b)(7)…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price
March 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 EXACT SCIENCES CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
March 1, 2023	EX-99.1	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes EXHIBIT 99.1 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., Feb. 23, 2023 — Exact Sciences Corp. (Nasdaq: EXAS) (the “Comp
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 EXACT SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
March 1, 2023	EX-4.2	Fourth Supplemental Indenture, dated March 1, 2023, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.00% Convertible Senior Notes due EXHIBIT 4.2 EXACT SCIENCES CORPORATION 2.0% Convertible Senior Notes due 2030 FOURTH SUPPLEMENTAL INDENTURE Dated as of March 1, 2023 to INDENTURE Dated as of January 17, 2018 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE 1 Scope of Fourth Supplemental Indenture; Definitions 1 SECTION 1.01. Scope of Fourth Supplemental Indenture 1 SECTION 1.02. Definition
February 21, 2023	EX-99	Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter
February 21, 2023	EX-10.32	EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY EXHIBIT 10.32 EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY 1.Introduction. This Equity Award Death, Disability and Retirement Policy (the “Policy”) specifies the treatment of each outstanding equity award (an “Equity Award”) granted by Exact Sciences Corporation, a Delaware corporation (including any successor thereto, the “Company”), in the event of the Death, D
February 21, 2023	EX-21	SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant’s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
February 21, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re
February 21, 2023	EX-10.17	CONSULTING AGREEMENT EXHIBIT 10.17 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into between Exact Sciences Corporation, a Delaware corporation (the “Company”), and D. Scott Coward, an individual (“Consultant”). The Company desires to retain the services of Consultant and Consultant desires to provide consultation to the Company. In consideration of the mutual covenants and promises cont
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 EXACT SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
February 10, 2023	SC 13G/A	EXAS / EXACT Sciences Corporation / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 9, 2023	SC 13G/A	EXAS / EXACT Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Exact Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 7, 2023	SC 13G/A	EXAS / EXACT Sciences Corporation / BlackRock Inc. Passive Investment us30063p1057020723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) EXACT SCIENCES CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 30063P105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 6, 2023	SC 13G/A	EXAS / EXACT Sciences Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 EXACT SCIENCES CO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 9, 2023	EX-99	Exact Sciences Announces Preliminary Fourth Quarter 2022 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2022 Results Preliminary fourth quarter highlights: •Expected total fourth quarter revenue, excluding COVID-19 testing, increase
December 30, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 EXACT SCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
November 3, 2022	EX-99	Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability Third quarter highlights ?Total third quart
November 3, 2022	EX-10.1	EMPLOYMENT AGREEMENT EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of 9/2/2022 (the ?Effective Date?), by and between Brian Baranick (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its General Manager, Precision Oncology, and Employe
November 3, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exac
September 12, 2022	SC 13G/A	EXAS / EXACT Sciences Corporation / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) EXACT SCIENCES CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30063P105 (CUSIP NUMBER) August 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is
August 2, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
August 2, 2022	EX-FILING FEES	Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EXHIBIT 107.1 Calculation of Filing Fee Tables ……Form S-8…….. (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offeri
August 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact nam
August 2, 2022	EX-99	Exact Sciences Announces Second Quarter 2022 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Morry Smulevitz Exact Sciences Corp. [email protected] 608-345-8010 For Immediate Release Exact Sciences Announces Second Quarter 2022 Results Second quarter highlights •Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision
August 2, 2022	S-8	As filed with the Securities and Exchange Commission on August 2, 2022 As filed with the Securities and Exchange Commission on August 2, 2022 Registration No.
June 30, 2022	EX-10.3	Receivables Purchase Agreement dated as of June 29, 2022 by and among the Various Entities listed on Schedule I hereto, as Originators, Exact Sciences Laboratories, LLC, as the initial Servicer, Exact Sciences Corporation, as Buyer EXHIBIT 10.3 Receivables Purchase Agreement dated as of June 29, 2022 by and among the Various Entities listed on Schedule I hereto, as Originators, Exact Sciences Laboratories, LLC, as the initial Servicer, and Exact Sciences Corporation, as Buyer Table of Contents Page ARTICLE I AGREEMENT TO PURCHASE AND SELL 2 SECTION 1.1 Agreement To Purchase and Sell 2 SECTION 1.2 Timing of Purchases 3 SECTIO
June 30, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 30, 2022	EX-10.2	Receivables Purchase Agreement dated as of June 29, 2022 by and among Exact Sciences Corporation, as Seller, Exact Sciences Laboratories, LLC, as the initial Servicer, Exact Receivables LLC, as Buyer EXHIBIT 10.2 Receivables Purchase Agreement dated as of June 29, 2022 by and among Exact Sciences Corporation, as Seller, Exact Sciences Laboratories, LLC, as the initial Servicer, and Exact Receivables LLC, as Buyer Table of Contents Page ARTICLE I AGREEMENT TO PURCHASE AND SELL 2 SECTION 1.1 Agreement To Purchase and Sell 2 SECTION 1.2 Timing of Purchases 3 SECTION 1.3 Consideration for Purchase
June 30, 2022	EX-10.1	Receivables Financing Agreement Dated as of June 29, 2022 by and among Exact Receivables LLC, as Borrower, The Persons from Time to Time Party Hereto, as Lenders and Group Agents, PNC Bank, National Association, as Administrative Agent, Exact Science EXHIBIT 10.1 Receivables Financing Agreement Dated as of June 29, 2022 by and among Exact Receivables LLC, as Borrower, The Persons from Time to Time Party Hereto, as Lenders and Group Agents, PNC Bank, National Association, as Administrative Agent, Exact Sciences Laboratories, LLC, as initial Servicer and PNC Capital Markets LLC, as Structuring Agent Table of Contents Section Heading Page Article
June 29, 2022	11-K	United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PUR
June 10, 2022	EX-10.1	AMENDMENT NO. 1 EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 AMENDMENT NO. 1 TO EXACT SCIENCES CORPORATION 2019 OMNIBUS LONG-TERM INCENTIVE PLAN This AMENDMENT NO. 1 (the ?Amendment?) amends the 2019 OMNIBUS LONG TERM INCENTIVE PLAN (the ?Existing Plan?; as amended hereby, the ?Plan?) of EXACT SCIENCES CORPORATION, a Delaware corporation (the ?Company?). Statement of Purpose The Existing Plan was originally approved by the Company?s Board of Di
June 10, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fil
June 10, 2022	EX-10.2	EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on June 9, 2022) EXHIBIT 10.2 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on June 9, 2022) Article 1?Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined in
May 20, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive
May 2, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) …………….…………… Exact Sciences Corporation ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables ??424(b)(7)??.. (Form Type) ?????.????? Exact Sciences Corporation ??????????.. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum (2) Aggregate Offering Price
May 2, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission File
May 2, 2022	424B7	EXACT SCIENCES CORPORATION 265,186 Shares of Common Stock Table of Contents PROSPECTUS SUPPLEMENT (To prospectus dated June 1, 2020) EXACT SCIENCES CORPORATION 265,186 Shares of Common Stock This prospectus supplement relates to the resale of up to 265,186 shares of our common stock, par value $0.
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 29, 2022	DEF 14A	Schedule 14A filed on April 2 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????)? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by
April 26, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission F
April 26, 2022	EX-10.1	EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 11, 2022) EXHIBIT 10.1 EXACT SCIENCES CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (As amended and restated on March 11, 2022) Article 1?Purpose. This 2010 Employee Stock Purchase Plan, as amended and restated (the "Plan"), is intended to encourage stock ownership by all eligible employees of Exact Sciences Corporation (the "Company"), a Delaware corporation, and its Participating Subsidiaries (as defined
April 26, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35092 EXACT SCIENCES CORPORATION (Exact na
April 26, 2022	EX-99	Exact Sciences announces first quarter 2022 results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences announces first quarter 2022 results ?Total first quarter revenue of $487M, including Screening revenue of $307M, Precision Oncology revenue of $153M, and COVID-19 testing r
April 26, 2022	EX-10.2	Exact Sciences Corporation Non-Employee Director Compensation Policy EXHIBIT 10.2 Exact Sciences Corporation Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy of Exact Sciences Corporation, a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Company
March 10, 2022	SC 13G/A	EXAS / EXACT Sciences Corporation / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) EXACT SCIENCES CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30063P105 (CUSIP NUMBER) February 28, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule
February 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 EXACT SCIENCES CORPORATION (Exact name of re
February 22, 2022	EX-99	Exact Sciences Announces Fourth Quarter 2021 Results Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 Media Contact: Katie Boyce Exact Sciences Corp. [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Fourth Quarter 2021 Results ?Total fourth quarter revenue of $474M, including Screening revenue of $278M, Precision Oncology revenue of $149M, and COVID-19 testing
February 22, 2022	EX-21	SUBSIDIARIES OF EXACT SCIENCES CORPORATION EXHIBIT 21 SUBSIDIARIES OF EXACT SCIENCES CORPORATION Registrant?s consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary.
February 22, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commissio
February 22, 2022	EX-10.15	EMPLOYMENT AGREEMENT EXHIBIT 10.15 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is entered into effective as of October 11, 2021 (the ?Effective Date?), by and between Everett Cunningham (?Employee?) and Exact Sciences Corporation, a Delaware corporation (the ?Company,? and together with Employee, the ?Parties?). WHEREAS, the Company desires to employ Employee as its Executive Vice President, Head of S
February 14, 2022	SC 13G/A	EXAS / EXACT Sciences Corporation / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 exas13gadec21.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) EXACT SCIENCES CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30063P105 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pur
February 11, 2022	SC 13G/A	EXAS / EXACT Sciences Corporation / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Exact Sciences Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
February 10, 2022	SC 13G/A	EXAS / EXACT Sciences Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Exact Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 30063P105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
February 9, 2022	SC 13G	EXAS / EXACT Sciences Corporation / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 4, 2022	SC 13G	EXAS / EXACT Sciences Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EXACT SCIENCES CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 30063P105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 4, 2022	SC 13G	EXAS / EXACT Sciences Corporation / BlackRock Inc. Passive Investment SC 13G 1 us30063p1057020422.txt us30063p1057020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) EXACT SCIENCES CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 30063P105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriat
January 28, 2022	EX-3.1	SIXTH AMENDED AND RESTATED EXACT SCIENCES CORPORATION (As of January 25, 2022) TABLE OF CONTENTS Exhibit 3.1 SIXTH AMENDED AND RESTATED BY-LAWS OF EXACT SCIENCES CORPORATION (As of January 25, 2022) BY-LAWS TABLE OF CONTENTS Page Article 1 - STOCKHOLDERS 1 1.1 PLACE OF MEETINGS 1 1.2 ANNUAL MEETING 1 1.3 SPECIAL MEETINGS 1 1.4 NOTICE OF MEETINGS 1 1.5 VOTING LIST 1 1.6 QUORUM 1 1.7 ADJOURNMENTS, ETC 2 1.8 VOTING AND PROXIES 2 1.9 ACTION AT MEETING 2 1.10 INTRODUCTION OF BUSINESS AT MEETINGS 3
January 28, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 10, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 10, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission
January 10, 2022	424B7	CALCULATION OF REGISTRATION FEE Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-238845 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered (1) Proposed Maximum Offering Price per share (2) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee (3) Common Stock, par value $0.01 per share 1,070,410 $73.86 $79,060,483 $7,328.91 (1) Purs
January 10, 2022	EX-99.1	Exact Sciences Announces Preliminary Fourth Quarter 2021 Results Exhibit 99.1 Investor Relations Contact: Megan Jones [email protected] 608-535-8815 Media Contact: Katie Boyce [email protected] 608-710-3903 For Immediate Release Exact Sciences Announces Preliminary Fourth Quarter 2021 Results ?Expected total fourth quarter revenue of $472-475M, including Screening revenue of $277-278M, Precision Oncology revenue of $148.5-149.5M, and COVID-19
January 10, 2022	EX-99.2	Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients PreventionGenetics’ comprehensive genetic testing portfolio complements Exact Sciences’ advanced cancer tests, enabling disease preve Exhibit 99.2 Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients PreventionGenetics? comprehensive genetic testing portfolio complements Exact Sciences? advanced cancer tests, enabling disease prevention and earlier cancer detection to benefit patients across decades of life Foundational laboratory and skilled team with experience in
January 10, 2022	EX-99.3	Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients Agreement grants a license to Exact Sciences for OncXerna’s Xerna™ TME Panel adding to its comprehensive tumor profiling solution, GEM E Exhibit 99.3 Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients Agreement grants a license to Exact Sciences for OncXerna?s Xerna? TME Panel adding to its comprehensive tumor profiling solution, GEM ExTra? Arrangement expands Exact Sciences? ability to support immuno-oncology clinical development programs MADISON, Wis., and WALTHAM, Ma

EXAS / Exact Sciences Corporation - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?